Detection of IgG anti-beta2 glycoprotein-I antibodies in Saudi patients with systemic lupus erythematosis

Authors

• Faris Q. Alenzi, Associate Professor of Immunology and Consultant Immunologist, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, PO Box 422 Al-Kharj 11942, Kingdom of Saudi Arabia. Tel. +966 (1) 5454518. Fax. +966 (1) 5454586. E-mail: falenzi{at}ksu.edu.sa

Abstract

OBJECTIVE: To develop an assay for the measurement of this anti-human beta2-glycoprotein I a-beta2-GPI METHODS: This study was conducted from September 2004 to December 2006. The patients attending the Rheumatology Clinic were chosen from several centers in the Eastern region of Saudi Arabia because they had complications. An enzyme-linked immunosorbent ELISA assay was optimized and developed to measure IgG a-beta2-GPI antibody levels in humans. Fifty normal blood donors and 50 systemic lupus erythrematosis SLE patients were selected for this experiment. RESULTS: Raised IgG a-beta2-GPI antibody levels were found in 80% of SLE patients. Interestingly, raised IgG a-beta2-GPI antibody levels were associated with the presence of venous thrombosis and thrombocytopenia. CONCLUSION: The real value of IgG a-beta2-GPI as a predictor for the future clinical complications needs to be confirmed in prospective controlled studies investigating clinical complications in relationship to IgG a-beta2-GPI and to other risk factors for thrombosis.

Article Type

Research Article

First Page

594

Last Page

599

Recommended Citation

Alenzi, Faris Q. (2008) "Detection of IgG anti-beta2 glycoprotein-I antibodies in Saudi patients with systemic lupus erythematosis," Saudi Medical Journal: Vol. 29: Iss. 4, Article 21.
DOI: https://doi.org/10.15537/1658-3175.4303